MedTrace Logo

SpareBrain - Mechanisms and Prevention of Secondary Brain Injury in Subarachnoid Haemorrhage

NCT02026596 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 61

Last updated 2017-10-31

No results posted yet for this study

Summary

Subarachnoidal hemorrhage (SAH) is a cause of long-term disability and death. Annually about 1000 people in Finland suffer from SAH, their average age being under 50 years. SAH has a mortality rate of 12 % acutely and 40 % of patients die within a month from admission to hospital. In addition, 30 % of the surviving patients remain with neurological deficits. Most survivors of the primary insult suffer from secondary injury during the first 2-3 weeks from the insult.

Despite the advances in neurosurgical and -radiological techniques and intensive care, the mortality and morbidity rates in SAH have not changed in recent years. There is still only limited understanding of the mechanisms of secondary insults causing brain injury after SAH.

In this study the investigators are aiming to clarify the timescale and mechanisms contributing to the secondary insults. The investigators also explore usability of novel biomarkers to guide treatment of the patients suffering from SAH.

Conditions

  • Aneurysmal Subarachnoid Hemorrhage

Interventions

PROCEDURE

Magnetic resonance imaging

PROCEDURE

Cerebral microdialysis catheter insertion

Is inserted only when invasive intracranial pressure monitoring is required. The same route with pressure probe is used for insertion.

Sponsors & Collaborators

  • Tampere University Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • Finland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02026596 on ClinicalTrials.gov